Antiga, Emiliano <br/><br/>
Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.  [electronic resource] 

 -  Journal of clinical immunology  Dec 2012 
 - 1221-32 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1573-2592 
<br/><br/><label>Standard No.: </label>10.1007/s10875-012-9716-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acitretin--pharmacology<br/>Adult<br/>Aged<br/>Anti-Inflammatory Agents, Non-Steroidal--pharmacology<br/>CD8-Positive T-Lymphocytes--drug effects<br/>Dermatitis, Atopic--blood<br/>Down-Regulation--drug effects<br/>Drug Administration Schedule<br/>Etanercept<br/>Female<br/>Humans<br/>Immunoglobulin G--pharmacology<br/>Interleukin-10--genetics<br/>Interleukin-17--genetics<br/>Keratolytic Agents--pharmacology<br/>Lymphocyte Count<br/>Male<br/>Middle Aged<br/>Psoriasis--blood<br/>Receptors, Tumor Necrosis Factor--therapeutic use<br/>Signal Transduction--drug effects<br/>Skin--drug effects<br/>Th1 Cells--drug effects<br/>Th17 Cells--drug effects<br/>Th2 Cells--drug effects<br/>Treatment Outcome